41L Stock Overview
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Laboratorios Farmaceuticos Rovi, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €62.10 |
| 52 Week High | €91.30 |
| 52 Week Low | €51.70 |
| Beta | 0.48 |
| 11 Month Change | -18.34% |
| 3 Month Change | -18.77% |
| 1 Year Change | 19.08% |
| 33 Year Change | 1.80% |
| 5 Year Change | 160.92% |
| Change since IPO | 1,314.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 41L | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.5% | -10.1% | -1.5% |
| 1Y | 19.1% | -21.6% | 7.9% |
Return vs Industry: 41L exceeded the German Pharmaceuticals industry which returned -24.1% over the past year.
Return vs Market: 41L exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| 41L volatility | |
|---|---|
| 41L Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 41L has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 41L's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,137 | Juan Lopez-Belmonte Encina | www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi.
Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary
| 41L fundamental statistics | |
|---|---|
| Market cap | €3.18b |
| Earnings (TTM) | €165.00m |
| Revenue (TTM) | €799.25m |
19.3x
P/E Ratio4.0x
P/S RatioIs 41L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 41L income statement (TTM) | |
|---|---|
| Revenue | €799.25m |
| Cost of Revenue | €310.33m |
| Gross Profit | €488.92m |
| Other Expenses | €323.92m |
| Earnings | €165.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.23 |
| Gross Margin | 61.17% |
| Net Profit Margin | 20.64% |
| Debt/Equity Ratio | 20.1% |
How did 41L perform over the long term?
See historical performance and comparison